Xencor is a clinical-stage biopharmaceutical company which focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The product candidates include immune inhibitors for the treatment of autoimmune diseases, asthma and allergic diseases, acute myeloid leukemia, B-cell malignancies, non-Hodgkin lymphomas and chronic lymphocytic leukemia and multiple myeloma.